About Lipocine
Lipocine (NASDAQ:LPCN) is a biopharmaceutical company focused on the development of innovative oral drug delivery solutions for the treatment of various diseases, including testosterone deficiency, non-alcoholic steatohepatitis (NASH), hypogonadism, and others. Leveraging its proprietary drug delivery technologies, Lipocine aims to improve patient outcomes by enhancing the efficacy, safety, and convenience of pharmaceutical products. The company's pipeline features several projects in various stages of development, targeting conditions that have a significant impact on the quality of life for patients. By focusing on unmet medical needs and leveraging cutting-edge science, Lipocine strives to become a pioneer in the field of drug delivery and therapeutics, with the ultimate objective of providing innovative treatments that can significantly improve patient care.
Snapshot
Operations
Produtos e/ou serviços de Lipocine
- TLANDO, a proprietary oral testosterone product for testosterone replacement therapy in adult males with hypogonadism.
- LPCN 1144, an oral product candidate targeting non-alcoholic steatohepatitis (NASH).
- LPCN 1148, designed for treating severe alcoholic hepatitis (SAH) with oral dosing.
- LPCN 1107, aimed at preventing preterm birth, marking a significant advance in maternal health.
- An oral testosterone replacement therapy product specifically designed for patients with chronic kidney disease.
- Development of pediatric formulations for various treatments, focusing on improving child health care.
equipe executiva do Lipocine
- Dr. Mahesh V. Patel Ph.D.Co-Founder, Interim Principal Financial Officer, Director, President & CEO
- Ms. Krista FogartyPrincipal Accounting Officer & Corporate Controller
- Dr. Nachiappan Chidambaram Ph.D.Senior Vice President of Research & Development
- Mr. Logan MorseVice President of Sales, Marketing & Operations
- Dr. Anthony DelConte M. D., M.D.Chief Medical Director